BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20857093)

  • 41. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
    Potkin SG; Preskorn S; Hochfeld M; Meng X
    J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
    Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
    Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
    Wang JS; DeVane CL
    Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
    Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
    Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial.
    Florian J; van der Schrier R; Gershuny V; Davis MC; Wang C; Han X; Burkhart K; Prentice K; Shah A; Racz R; Patel V; Matta M; Ismaiel OA; Weaver J; Boughner R; Ford K; Rouse R; Stone M; Sanabria C; Dahan A; Strauss DG
    JAMA; 2022 Oct; 328(14):1405-1414. PubMed ID: 36219407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Morphine or oxycodone in cancer pain?
    Heiskanen TE; Ruismäki PM; Seppälä TA; Kalso EA
    Acta Oncol; 2000; 39(8):941-7. PubMed ID: 11207001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.
    Moody DE; Walsh SL; Rollins DE; Neff JA; Huang W
    Clin Pharmacol Ther; 2004 Aug; 76(2):154-66. PubMed ID: 15289792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia.
    Olesen AE; Upton R; Foster DJ; Staahl C; Christrup LL; Arendt-Nielsen L; Drewes AM
    Clin Pharmacokinet; 2010 Dec; 49(12):817-27. PubMed ID: 20873879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
    Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
    Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
    Lemberg KK; Kontinen VK; Siiskonen AO; Viljakka KM; Yli-Kauhaluoma JT; Korpi ER; Kalso EA
    Anesthesiology; 2006 Oct; 105(4):801-12. PubMed ID: 17006080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
    Moody DE; Liu F; Fang WB
    J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
    Fliegert F; Kurth B; Göhler K
    Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and pharmacodynamics of controlled-release opioids.
    Kaiko RF
    Acta Anaesthesiol Scand; 1997 Jan; 41(1 Pt 2):166-74. PubMed ID: 9061102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
    Hao GT; Zhou HY; Gao HZ; Qu HY; Liang YG; Li YY; Dong RH; Zhang LJ; Wang XF; Liu ZY
    Pharmacol Rep; 2014 Feb; 66(1):153-8. PubMed ID: 24905321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
    Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
    Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
    Kharasch ED; Whittington D; Hoffer C; Krudys K; Craig K; Vicini P; Sheffels P; Lalovic B
    Clin Pharmacokinet; 2005; 44(7):731-51. PubMed ID: 15966756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.